Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06691893 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients
A Phase 3 study of Pancreatitis and Exocrine Pancreatic Insufficiency (EPI), sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06691893 is a Phase 3 study of Pancreatitis and Exocrine Pancreatic Insufficiency (EPI) that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 619-participant average among 17 other Pancreatitis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06691893, a Phase 3 study of Pancreatitis and Exocrine Pancreatic Insufficiency (EPI), is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This research aims to improve the management of exocrine pancreatic insufficiency (EPI), a condition that can develop after pancreatitis, a painful inflammation of the pancreas. EPI occurs when the pancreas does not produce enough enzymes to help the body properly digest food. While pancreatic enzyme replacement therapy (PERT) is commonly used to manage EPI symptoms, it can be challenging for people who rely on feeding tubes. RELiZORB, could help these patients by simplifying the delivery of the enzymes they need. However, RELiZORB has only been studied in people with EPI caused by cystic fibrosis, so its effectiveness in pancreatitis patients remains unknown. This study aims to determine whether RELiZORB is effective for individuals requiring feeding tube support after pancreatitis.
Conditions Studied
Interventions
- DEVICE RELiZORB
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06691893
The ClinicalTrials.gov registry entry for NCT06691893 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 619-participant average among 17 other Pancreatitis trials with a reported enrollment target (90% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which RELiZORB is the first listed.
NCT06691893 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06691893 about?
NCT06691893 is a clinical study titled "Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients". This research aims to improve the management of exocrine pancreatic insufficiency (EPI), a condition that can develop after pancreatitis, a painful inflammation of the pancreas. EPI occurs when the pancreas does not produce enough enzymes to help the body properly digest food. While pancreatic enzym...
What is the current status of trial NCT06691893?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-03-28. Estimated completion is 2027-07-15.
What conditions does trial NCT06691893 study?
This clinical trial studies the following conditions: Pancreatitis, Exocrine Pancreatic Insufficiency (EPI).
What interventions are being tested in trial NCT06691893?
The interventions under investigation include: RELiZORB (DEVICE).
Who is sponsoring clinical trial NCT06691893?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06691893 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
RECRUITING
-
Building and Sustaining Exercise Habits for Adults With Type 1 Diabetes
RECRUITING · NA
-
Scrambler Therapy in Chronic Pancreatitis
RECRUITING · NA
-
PROMs After Pancreatectomy
RECRUITING
-
Pancreas Registry and High Risk Registry
RECRUITING
-
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
RECRUITING
Explore more on PlainTrial
Pancreatitis
All registered trials for this condition
Exocrine Pancreatic Insufficiency (EPI)
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.